The results showed that the two-dose vaccine, which is the first vaccine approved for use in emergency situations and one of the most popular vaccines in the United States and other countries, “may also provide protection against the most contagious variants of the Coronavirus epidemic around the world.”
One study was published in the New England Journal of Medicine and is based on data from more than 200,000 Qataris. All were vaccinated with the Pfizer-BioNTech vaccine. Studies have shown this
Study participants were found to be resistant to a virus variant that was first identified in the United Kingdom with an efficiency of 89.5 per cent. A rate of 75 percent was set against the version also called B.1.351, which was first set in South Africa in professional circles.
The second study was published in the Dutch medical weekly The Lancet, but also edited in New York, London and Beijing, and is based on data from more than 230,000 Israeli residents infected with the infection from January 24 to April 3. Researchers from the Israeli Ministry of Health and Pfizer found this
The vaccine was 95 percent effective in preventing further disease against more infectious variants in people over 16 years of age. In people 85 years of age or older, the Pfizer-BioNTech vaccine showed 94% effectiveness against mutations.
Researchers at Pfizer-BioNTech are constantly researching the need for a booster shot for coronavirus infection. Experts believe that a possible third vaccination may trigger a greater immune response to more infectious variants in people who have already been vaccinated..
Cover photo: Getty Images
